PENZBERG, Germany--(BUSINESS WIRE)-- Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.
Viability and cytotoxicity assays are routinely used to determine how various treatments potentially perturb cell homeostasis leading to decreased viability and increased cytotoxicity. Many agents used for cancer therapeutics modulate the intricate balance between cell proliferation and cell death. The ultimate aim of cancer therapy is to reduce or eliminate cancerous cells in the body, thus shifting the balance by either increasing cell death or decreasing cell proliferation.
In a recent study (1) of Ning Ke and Yama Abassi of ACEA Bioscience in San Diego, Roche’s (Pink Sheets: RHHBY) (SWX:RO) (SWX:ROG) xCELLigence System had been used for studying cell viability and cell death when testing various cytotoxic compounds. Real-time impedance-based cell analyzers, such as the RTCA SP Instrument and E-Plate 96, could identify the onset of cytotoxicity using continuous impedance-based monitoring of cell viability, pinpointing when maximal effects occur. Furthermore, the instrument identified the best time point, i.e., when CI values are at their lowest, for conducting functional endpoint assays that examine cell fate transitions, such as apoptosis and cell cycling, in greater detail. The xCELLigence System also proved to be suitable for identifying culture wells with inappropriate cell numbers at the beginning of the assay, thus minimizing the role of cell seeding and culture plate edge artifacts during data analysis.
Cell death occurs through a spectrum of distinct morphological and biochemical pathways culminating in apoptosis, necrosis and autophagy. It is important to understand the different modes of cell death mediated by cytotoxic agents to decipher the mechanisms of drug action and identify significant side effects. The direct effect of compound treatment on cell death is often transient and difficult to capture using standard endpoint assays. For example, apoptosis occurs only during a short window of time, often within just hours, and is frequently followed by secondary necrotic events. It is therefore crucial to conduct relevant assays, measuring either cell viability or cell death, at the optimal experimental time points. Considering that the kinetics of cell killing is likely to be different for different compounds, it is important to monitor cell viability and toxicity continuously, to pinpoint the optimal time points for conducting endpoint assays and to gain the necessary mechanistic information.
The xCELLigence System allows for real-time, label-free and dynamic monitoring of cellular phenotypic changes by measuring electrical impedance. The system measures impedance using interdigitated microelectrodes integrated into the bottom of each well of the tissue culture E-Plates 96. Impedance measurements are displayed as Cell Index (CI) values, providing quantitative information about the biological status of the cells, including cell number, cell viability and cell morphology. Impedance-based monitoring of cell viability correlates to cell number and MTT-based readout. The kinetic aspect of impedance-based cell viability measurements provides the necessary temporal information, for instance, when compounds of interest are used to induce cytotoxic effects. In particular, the xCELLigence System is ideal for pinpointing optimum time points, i.e., when cytotoxic compounds achieve their maximum effect, as indicated by the lowest CI values in cytotoxicity and cell death assays.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
(1) Focus Application Note “Compound-induced Cytotoxicity, Roche Applied Science, 2010.
For life science research only. Not for use in diagnostic procedures.
All trademarks used or mentioned in this release are protected by law.
XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of
ACEA Biosciences, Inc. in the US.
Other brands or product names are trademarks of their respective holders.
CONTACT:
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
KEYWORDS: United States Europe North America California Germany
INDUSTRY KEYWORDS: Stem Cells Surgery Health Genetics Hospitals Medical Devices Oncology Pharmaceutical Research FDA Medical Supplies Science
MEDIA:
| Logo |